biopharm, that is correct. It will of course for those that read all the information from PACER also attract the attention that there is a SECOND clinical trial besides the 2nd ln NSCLC PII which appears in the PPHM vs CSM filings. The fact that it are the CSM lawyers that mentioned it at least takes away the doubt that it is just PPHM saying it.
I am waiting to find the beginning of statements/listings/evidence/PR/etc that could identify what file that was or find a peace of information that shows what other CTs of PPHM CSM was working on.
My primary candidate remains the 1st ln NSCLC PII CT because of the abnormal results.
Like to know some of the details in the PPHM / Abbvie agreement.
Was it only NSCLC or a broader application. What percent did we own going forward of that application. Did Abbive agree to foot the cost of the Phase 3.
Market Data 
Markets 
AI
